Besides T-cell infiltrate and neoantigen load55,56, other factors have recently been proposed as biomarkers to predict the effectiveness of immunotherapy, including PD-L1 expression57, antigen presentation defects58, interferon signaling59, mismatch repair deficiency60, tumor aneuploidy61, and gut microbiota62. This evidence concerns the gene CD274 and neoplasm.